趙瑜,助理教授、研究員、博士生導師。2006年7月獲得青島大學醫學院生物技術專業學士學位,2012年7月獲得南開大學生命科學學院生物化學與分子生物學專業博士學位。作為第一完成人,獲全國顛覆性技術創新大賽優秀獎1項,中國健康長壽創新大賽三等獎1項。獲得美國生物醫學Kendall C. Edward獎學金1項,遼寧省科技進步一等獎。獲得天津市杰出青年科學基金、天津市重點項目等資助。
院校引進人才,2021年加入院校,曾在2012年7月進入梅奧醫院攻讀博士后,并于2017年7月任梅奧醫院研究助理,2018年5月至2021年2月任梅奧醫院助理教授。
長期從事新型核藥和核藥新靶點研究,提出核藥靶點研發不同于傳統藥物的“司機-乘客蛋白互換”新理論和核藥-免疫聯合治療新策略;創立核藥高效入核新技術,節省核素、降低核藥使用成本2倍以上,解決核藥診療貴的難題。承擔天津市杰青項目等5項國家和省部級科研課題,在Nature Medicine等雜志發表論文50余篇,H指數29,2篇被引次數破200,4篇被引破100,3篇被國際專利引用,進入臨床研究。主編國際專著章節2部,參編1部。培養博士、碩士、博士后10余名,研究生獲國家獎學金2人。
1. Shao C#, Zhang Y#, Li H#, Chen J#, Huang T, Li J, Wen S, Wang S, Fan S, Zhao Y*. Radiotherapy-resistant prostate cancer cells escape immune checkpoint blockade through the senescence-related ataxia telangiectasia and Rad3-related protein. Cancer Commun (Lond). 2024 Dec 19. doi: 10.1002/cac2.12636.
2. Wen S#, Wei Y#, Zen C, Xiong W, Niu Y, Zhao Y*. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine. Molecular Cancer. 2020 Dec 12;19(1):171. (C100)
3. Zhang P.#, Wang D.#, Zhao Y.#, Ren S.#, Gao K.#, Ye Z., Wang S., Pan C.W., Zhu Y., Yan Y., Yang Y., Wu D., He Y., Zhang J., Lu D., Liu X., Yu L., Zhao S., Li Y., Lin D., Wang Y., Wang L., Chen Y., Sun Y.*, Wang C.*, Huang H.*, Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation, Nature Medicine, 23 (2017) 1055-1062. (C100)
4. Zhao Y#, Ding L#, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L#, Huang H#. EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis. EMBO J. 2019 Mar 1;38(5):e99599. (C100)
5. Zhao Y, Wang L, Ren S, Wang L, Blackburn PR, McNulty MS, Gao X, Qiao M, Vessella RL, Kohli M, Zhang J, Karnes RJ, Tindall DJ, Kim Y, MacLeod R, Ekker SC, Kang T, Sun Y#, Huang H*. Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. Cell Rep. 2016 Apr 19;15(3):599-610. (C100)
6. Huang Y, Li J, Wang S, Tian H*, Fan S*, Zhao Y*. Diselenide-based nanoparticles enhancing the radioprotection to the small intestine of mice. J Nanobiotechnology. 2025 Mar 22;23(1):236. doi: 10.1186/s12951-025-03276-3.
7. Yue T, Dong Y, Huo Q, Li W, Wang X, Zhang S, Fan H, Wu X, He X, Zhao Y*, Li D*. Nicotinamide riboside alleviates ionizing radiation-induced intestinal senescence by alleviating oxidative damage and regulating intestinal metabolism. J Adv Res. 2025 Jun;72:421-432.
8. Li W, Wang X, Dong Y, Huo Q, Yue T, Wu X, Lu L, Zhang J, Zhao Y*, Dong H*, Li D*. Nicotinamide riboside intervention alleviates hematopoietic system injury of ionizing radiation-induced premature aging mice. Aging Cell. 2023 Nov;22(11):e13976.
9. Li H#, Zhao S, Jiang M, Zhu T, Liu J, Feng G, Lu L, Dong J, Wu X, Chen X, Zhao Y*, Fan S*. Biomodified Extracellular Vesicles Remodel the Intestinal Microenvironment to Overcome Radiation Enteritis. ACS Nano. 2023 Jul 25;17(14):14079-14098.
10. Dai D#, Yu J#, Huang T#, Li Y, Wang Z, Yang S, Li S, Li Y, Gou W, Li D, Hou W, Fan S*, Li Y*, Zhao Y*. PET imaging of new target CDK19 in prostate cancer. Eur J Nucl Med Mol Imaging. 2023 Jun 6.